Hypertension Care » read post

Hypertension and Diabetic Kidney Disease: Table of Contents


Hypertension and Diabetic Kidney Disease: Table of Contents
Hypertension and Diabetic Kidney Disease - An evaluation of the current and future Darusentan. 60. FG-3019. 61. KRX-101. 61. Pratosartan. 62. PTR-3173. 63. Pyridorin. 63. Ruboxistaurin (LY-333531)
Source: www.market-research-report.com

Email Article. Myogen Initiates Phase 3 Clinical Trial of Darusentan
Email Article. Myogen Initiates Phase 3 Clinical Trial of Darusentan in Patients with Resistant Hypertension Genetic Engineering & Biotechnology News - Biotechnology from Bench to
Source: www.genengnews.com

Deconstructing Myogen’s market cap - Nature Biotechnology
Myogen’s more promising drugs include darusentan, a selective endothelin receptor antagonist designed to treat treatment-resistant hypertension. Darusentan did well in phase 2
Source: www.nature.com

The World Hypertension Market 2007-2023 - market research report
The World Hypertension Market 2007-2023 The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global
Source: www.reportlinker.com

Myogen rockets on positive drug news - MarketWatch
BOSTON (MarketWatch) - Shares of Myogen rocketed over 60% on Thursday after it released positive clinical drug data on its high blood pressure drug darusentan.
Source: www.marketwatch.com

IndiaDaily - Gilead agreed to buy biotech company Myogen for $2.5
We have two product candidates in late-stage clinical development: ambrisentan for the treatment of pulmonary arterial hypertension (PAH) and darusentan for the treatment of
Source: www.indiadaily.com

10-Q: GILEAD SCIENCES INC - MarketWatch
our product candidates into more advanced clinical studies as well as the continuation of our clinical trials related to elvitegravir for HIV, darusentan for resistant hypertension
Source: www.marketwatch.com

Tags: , , , ,